论文部分内容阅读
目的:探讨标准三联疗法联合依卡倍特钠治疗幽门螺杆菌(Hp)相关十二指肠球部溃疡的临床效果。方法:选取2014年7月至2016年1月重庆市奉节县人民医院收治的Hp阳性的十二指肠球部溃疡患者100例,按临床随机数表法分成两组各50例。其中,治疗组采用依卡倍特钠+雷贝拉唑+呋喃唑酮+阿莫西林四联治疗;对照组采用胶体果胶铋+呋喃唑酮+阿莫西林+雷贝拉唑四联联治疗,观察两组患者治疗效果。结果:治疗组与对照组总有效率与不良反应率比较,差异均无统计学意义(P>0.05)。结论:依卡倍特钠+雷贝拉唑+阿莫西林+呋喃唑酮可作为Hp阳性的十二指肠球部溃疡根除Hp的新方法。
Objective: To investigate the clinical effect of standard triple therapy combined with icarubat sodium in the treatment of Helicobacter pylori (Hp) -related duodenal ulcer. Methods: One hundred patients with Hp-positive duodenal ulcer admitted to Fengjie County People’s Hospital of Chongqing from July 2014 to January 2016 were randomly divided into two groups of 50 cases according to the clinical random number table. Among them, the treatment group used icarubicin + rabeprazole + furazolidone + amoxicillin quadruple therapy; control group using colloidal pectin bismuth + furazolidone + amoxicillin + rabeprazole quadruple joint therapy, observe two Group patients treatment effect. Results: There was no significant difference between the total effective rate and the adverse reaction rate in the treatment group and the control group (P> 0.05). Conclusion: Icaquat sodium + rabeprazole + amoxicillin + furazolidone can be used as a new method to eradicate Hp in Hp-positive duodenal ulcer.